cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cullinan Oncology Inc
2 own
1 watching
Current Price
$10.05
$0.49
(5.13%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
460.25M
52-Week High
52-Week High
15.89
52-Week Low
52-Week Low
7.782
Average Volume
Average Volume
2.06M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization460.25M
icon52-Week High15.89
icon52-Week Low7.782
iconAverage Volume2.06M
iconDividend Yield--
iconP/E Ratio--
What does the Cullinan Oncology Inc do?
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company s lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Cullinan Oncology Inc make?
News & Events about Cullinan Oncology Inc.
Globe Newswire
1month ago
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc.(Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announcedthat the first clinical data from its Phase 1 clinical study of CLN-619 in patients with advanced solid ...
Globe Newswire
3 months ago
CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan Oncology) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that its President and Chief Executive Officer, Nadim Ahmed, will present at Cowens ...
Globe Newswire
4 months ago
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc.(Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announcedthe U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ...
Globe Newswire
10 months ago
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan Oncology) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Financial Officer, Jeff Trigilio, ...
Globe Newswire
12 months ago
Updated data from Phase 1/2a study show median duration of response greater than 21 months and median progression-free survival of 12 months at 100 mg BID dose Confirmed overall response rate of 41% at 100 mg BID dose Continued favorable safety and tolerability profile observed in heavily pre-...
Frequently Asked Questions
Frequently Asked Questions
What is Cullinan Oncology Inc share price today?
plus_minus_icon
Can Indians buy Cullinan Oncology Inc shares?
plus_minus_icon
How can I buy Cullinan Oncology Inc shares from India?
plus_minus_icon
Can Fractional shares of Cullinan Oncology Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cullinan Oncology Inc stocks?
plus_minus_icon
What is today’s traded volume of Cullinan Oncology Inc?
plus_minus_icon
What is today’s market capitalisation of Cullinan Oncology Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cullinan Oncology Inc?
plus_minus_icon
What percentage is Cullinan Oncology Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cullinan Oncology Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$10.05
$0.49
(5.13%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PHATHOM PHARMACEUTICALS INC
PHATHOM PHARMACEUTICALS INC
$11.76
$0.04 (0.34 %)
NURIX THERAPEUTICS INC
NURIX THERAPEUTICS INC
$9.79
$0.06 (0.62 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$8.40
$0.02 (0.24 %)
Allakos Inc
Allakos Inc
$4.60
$-0.21 (-4.37 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
PHATHOM PHARMACEUTICALS INC
PHATHOM PHARMACEUTICALS INC
$11.76
$0.04 (0.34 %)
NURIX THERAPEUTICS INC
NURIX THERAPEUTICS INC
$9.79
$0.06 (0.62 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$8.40
$0.02 (0.24 %)
Allakos Inc
Allakos Inc
$4.60
$-0.21 (-4.37 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00